Compugen Ltd. announced on November 27, 2024, that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 12152084, titled 'Triple combination antibody therapies'. This patent covers the method of use for COM902, the company's reduced Fc anti-TIGIT antibody, and additional TIGIT backup antibodies.
The patent specifically protects the use of COM902 in a triple combination with any anti-PD-1 antibody and any anti-PVRIG antibody for the treatment of cancer. This expands Compugen's existing intellectual property, safeguarding its innovative approach to cancer immunotherapy.
The new patent is expected to expire no earlier than August 2037 in the United States, providing long-term protection for this strategic combination. This intellectual property expansion is a crucial part of Compugen's strategy to deliver innovative treatments and create shareholder value.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.